Brokerages Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $17.50

Immuneering Corporation (NASDAQ:IMRX) has received a consensus recommendation of “Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $17.50.

IMRX has been the subject of a number of recent research reports. UBS Group set a $14.00 price objective on Immuneering in a research note on Thursday, August 6th. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a report on Monday, July 20th. HC Wainwright assumed coverage on Immuneering in a research report on Thursday, August 6th. They set a “buy” rating and a $14.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th. Finally, Needham & Company LLC increased their price target on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th.

Institutional Trading of Immuneering

A number of hedge funds have recently bought and sold shares of IMRX. Empery Asset Management LP acquired a new position in shares of Immuneering in the fourth quarter worth about $17,601,000. State Street Corp increased its position in shares of Immuneering by 1,289.7% in the fourth quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after acquiring an additional 2,229,374 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Immuneering by 128.5% during the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after acquiring an additional 1,358,322 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Immuneering during the third quarter valued at approximately $6,602,000. Finally, Marshall Wace LLP lifted its position in shares of Immuneering by 162.4% in the 4th quarter. Marshall Wace LLP now owns 711,875 shares of the company’s stock valued at $4,684,000 after acquiring an additional 440,571 shares in the last quarter. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Price Performance

IMRX stock opened at $5.30 on Thursday. Immuneering has a 12 month low of $3.86 and a 12 month high of $10.08. The firm has a market cap of $342.91 million, a PE ratio of -5.10 and a beta of 0.43. The firm has a 50 day simple moving average of $4.73 and a 200 day simple moving average of $4.99.

Immuneering (NASDAQ:IMRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). As a group, sell-side analysts expect that Immuneering will post -1.07 earnings per share for the current year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.